InSphero

InSphero is a leader in the 3D cell culture market, providing industry-ready, scalable in vitro models that serve as alternatives to animal testing. The company's core technology enables the production of uniform, automation-compatible 3D spheroids and organoids for high-throughput screening in drug safety and efficacy applications. It operates primarily as a platform and products company, serving pharmaceutical, biotechnology, and academic partners with its Akura™ plates and specialized testing platforms. InSphero is positioned at the forefront of the regulatory shift towards human-relevant preclinical models.

Platform for producing reliable, scalable, and reproducible scaffold-free 3D cell culture models (spheroids & organoids) in automation-compatible Akura™ plates for high-throughput drug screening. Specialized platforms for liver safety, GI toxicology, oncology, and islet biology.

InSphero competes in the 3D cell culture and organ-on-a-chip market against companies like Emulate, Mimetas, CN Bio, and Corning, as well as academic spinoffs. Its key differentiators are its strong focus on industrial scalability, automation compatibility, and proven reproducibility for high-throughput screening, which are critical for pharmaceutical industry adoption.